PositiveID Corporation PSID
We are really excited about the upside potential of this morning’s featured company, PositiveID Corporation™ (OTCBB: PSID). The near-term on a ripening chart, as well as the long-term with an intriguing line of advanced technologies and high-level partnerships, are both looking decidedly bright for PSID.
As usual, we want to dive into the nuts and bolts of the company’s products before we take a look at the technicals of the chart. PositiveID’s futuristic line includes a number of different offerings, both existing and under development, that can really push the boundaries of point-of-care medical diagnostics, as well as real-time airborne pathogen and environmental contaminant detection.
PositiveID Molecular Diagnostic Technologies:
The Microfluidics-based Bioagent Networked Detector (M-BAND), is a sample collection, processing and detection system that analyzes air samples for the purpose of rapid bacterial, viral and toxic detection. It then delivers the data in real-time via a connected network. The system was developed by the company’s MicroFluidic Systems subsidiary under contract with the U.S. Department of Homeland Security from ’04 to ’09, during which time it received governent funding on the order of $30M.
The DragonFly cartridge system provides cell lysis, nucleic acid purification, PCR amplification and fluorescent detection on biological samples for the purposes of identifying environmental bacteria, human papilloma virus (HPV), and antibiotic resistant bacteria such as MRSA.
FireFly, which is one of the technologies currently under development, will allow first-response teams to perform many of the same diagnostic tasks as its predecessors, using a handheld display device which communicates wirelessly via Bluetooth with a smartphone or computer.
There is rising demand for the kind of technologies PSID develops, as well as increased government spending. Anthrax and Ricin scares, SARS & H1N1 crises, and the looming threat of bio-terrorism and chemical warfare have all been contributing factors to increased funding.
Both M-BAND and FireFly will also be topics of discussion when Chief Technology Advisor Dr. Kimothy Smith presents for PSID at the 21st International Conference for Biodetection Technologies, as outlined in the PR you’ll find below.
Also worthy of mention, is PSID’s partnership with aerospace and defense behemoth, The Boeing Company. It is Boeing that has become PositiveID’s exclusive distributor of the M-BAND for the DHS $3.1 billion BioWatch Gen-3 program. With bedfellows like Boeing and Homeland Security, we are really hyped up about the possibilities that the future holds for PositiveID Corp.
We have taken the liberty of preparing an assessment of the current PSID chart in graphic and video formats for your viewing convenience.
We are turning our attention to PSID at a good time, with the stock trading at a relative bottom. As you can see on the chart below, conditions are just beginning to look primed for sizable gains. Currently we are looking at resistance at the 20DMA of .27, the 50DMA of .34, the 100DMA of .40, and the 200DMA of .44. Returning to these levels from its current price, would afford us gains ranging from 42-132%
This Morning’s PR:
DELRAY BEACH, Jun 13, 2013 (GLOBE NEWSWIRE via COMTEX) — PositiveID Corporation (“PositiveID” or “Company”) (OTCBB:PSID), a developer of biological detection and diagnostics solutions, today announced it has published an updated report on market opportunities and positioning for its M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) and its new Firefly Dx system (“Firefly”) technologies. The report is available on PositiveID’s website at positiveidcorp.com
Recent Important Announcement:
DELRAY BEACH, Fla., June 4, 2013 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCBB:PSID), a developer of biological detection and diagnostics solutions, today announced that Chief Technology Advisor Dr. Kimothy Smith is a featured presenter at the 21st International Conference for Biodetection Technologies 2013 in Alexandria, VA, at the Hilton Alexandria Mark Center Conference Center. Dr. Smith is scheduled to present at 4 pm ET on June 18, 2013, and will discuss the Company’s technological advances in the detection and identification of biological threats, specifically its M-BAND (Microfluidics-based Bioagent Autonomous Networked Detector) and Firefly Dx detection system (“Firefly”).
More Information on PositiveID Corp, and its technologies an be found at: http://www.PositiveIDCorp.com.